Dapagliflozin 10 mg + Placebo tablet
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Non-Insulin-Dependent
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Trial Timeline
Apr 25, 2013 → Sep 11, 2018
NCT ID
NCT01730534About Dapagliflozin 10 mg + Placebo tablet
Dapagliflozin 10 mg + Placebo tablet is a phase 3 stage product being developed by AstraZeneca for Diabetes Mellitus, Non-Insulin-Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT01730534. Target conditions include Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01730534 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Non-Insulin-Dependent